THE EFFICACY AND SAFETY PROFILE OF ADVANCED THERAPY MEDICINAL PRODUCTS IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION
Abstract
Age-related macular degeneration is the main cause of loss of sight in the world. This review presents a current view on modern drugs used for the treatment of macular degeneration. A comparison effectiveness and safety profile of bevacizumab, ranibizumab, and pegaptanib aflibercept enables us to conclude that each of these compounds has its own advantages and disadvantages. Further study will develop rational schemes of their application.
About the Authors
R. N. Alyautdin
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
Russian Federation
B. K. Romanov
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
Russian Federation
V. K. Lepakhin
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
Russian Federation
V. A. Merculov
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
Russian Federation
N. A. Mironov
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
Russian Federation
References
1. Hadrill M. Macular degeneration treatment [webpage on the Internet]. Http://www.allaboutvision.com
2. Thomas M., Mousa S.S., Mousa S.A. Comparative effectiveness of aflibercept for treatment of patients with neovascular age-related macular degeneration.// Clin. Ophthal., 2013,7, 495-501
3. Stewart M.W. Clinical and differential utility of VEGF inhibitors in wet age –related vacular degeneration.// Clin. Ophthal., 2012, 6, 1175-1186
4. Kvanta A. Ocular angiogenesis: the role of growth factors.// Acta Ophthalmol. Scand., 2006, 84, 282-288
5. Penn J.S., Madan A., Caldwell L.D. Vascular endothelial growth factor in eye disease. // Prog. Retin. Eye Res., 2008, 27, 331-371
6. Fournier E., Birnbaum D., Borg J.P. Receptors for factors of the VEGF.// Bull. Cancer., 1997, 84, 397-405
7. Smith L.E., Kopchick J.J., Chen W. Essential role of growth hormone in iscemis–induced retinal neovascularisation. Science, 1997,276, 1706-1709
8. Bylsma G.W., Guymar R.H. Treatment of age-related macular degeneration.// Clin. Exp. Optom., 2005, 88, 322-334
9. Tsutsumi C., Sonoda K.H., Egashira K. et al. The critical role of ocular infiltrating macrophages in the development of choroidal neovascularisation.// J. Leukos. Biol. 2003, 74, 25-32
10. Folkman J. Angiogenesis: an organizing principle for drug discovery?// Nat Rev Drug Discov., 2007,6,273-286.
11. Sanro de Falco. Antiangiogenesis therapy: an update after the first decade.// Korean J Intern Med 2014, 29,1-11
12. Malhotra M., Majumdar D.K. Permeation through cornea. Indian J. Exp. Biol. 2001; 39: 11–24
13. Kawakami S., Yamamura K., Mukai T., et al: Sustained ocular delivery of tilisolol to rabbits after topical administration or intravitreal injection of lipophilic prodrug incorporated in liposomes. J. Pharm. Pharmacol. 2001; 53: 1157–61.
14. Barar J., Javadzadeh A.R., Omidi Y. Ocular novel drug delivery: impacts of membranes and barriers. Expert. Opin. Drug Deliv. 2008; 5(5): 567–81
15. Р. Н. Аляутдин, И. Н. Иежица, Р. Агарвал (R. Agarwal). Транспорт лекарственных средств через роговицу глаза. Вестник офтальм. 2014, №2
16. Lallemand F, Bayeaens O, Besseghir K et al. Cyclosporine delivery to the eye: pharmaceutical challenge. Eur. Pharm. Biopharm. 2003; 56: 307-319.
17. Р.Н. Аляутдин. Транспорт лекарственных веществ через гемато-энцефалический барьер: линия Мажино или волшебный Сезам?// Молек.мед., 2013, №3, 12-17
18. Bylsma J.V., Guymer R.H. Treatment of age-related macular degeration.//Clin. Exp. Optom. 2005, 234, 117-120
19. P. Ventrice, C. Leporini, J/F. Aloe, Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases.// .J Pharmacol Pharmacother.2013; 4(Suppl1): S38–S42
20. A. Ozkaya, Z. Alkin, Y. Karakucuk. Bevacizumab versus Ranibizumab on as-needed treatment regimen for neovascular agerelated macular degeneration in turkish patients.// ISRN Ophthalmol. 2013; 2013: 151027.
21. A. Manna, O. Oyede, B. Ning. Avastin and Lucentis: what do patients know? A prospective questionnaire survey.// JRSM Short Rep. Sep 2013; 4(9): 2042533313484146 22. K. K. Ciomur, J. Berlin. Aflibercept. // Clin.Cancer.Res., 2013, 19, 1920-1925
22. A.V. Lakhin, V.Z. Tarantul, L.V. Gening. Aptamers: problems, solutions, prospects.// Acta Natrure, 2013, №4, 34-43
23. C.A. Trujillo, A.A. Nery, J.M. Martis. Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology.// Clin. Ophthalmol., 2007, 1, 393-402.
Review
For citations:
Alyautdin R.N., Romanov B.K., Lepakhin V.K., Merculov V.A., Mironov N.A. THE EFFICACY AND SAFETY PROFILE OF ADVANCED THERAPY MEDICINAL PRODUCTS IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION. Safety and Risk of Pharmacotherapy. 2014;(1):12-17. (In Russ.)
Views:
569
Email this article 